Protalix Biotherapeutics News

Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

PR NewswireMay 3 18:50

NYSE American New 52-Week Highs And Lows

New Highs 0 COMPANY SYMBOL HIGH VOLUME ------- ------ ---- ------ New Lows 11 COMPANY SYMBOL LOW

Dow JonesApr 16 22:20

Earnings Call Summary | Protalix Biotherapeutics(PLX.US) Q4 2023 Earnings Conference

The following is a summary of the Protalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call Transcript:Financial Performance:Protalix reported Q4 revenues of $40.4 million, a significant increase of

Futu NewsMar 15 01:35 · Conference Call

Protalix BioTherapeutics GAAP EPS of $0.09 Misses by $0.01, Revenue of $65.49M Beats by $1.54M

Seeking AlphaMar 14 18:51

Press Release: Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results

Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results PR Newswire CARMIEL, Israel, March 14, 2024 Company to host conference call and webcast today at 8:30 a.m. EDT CARM

Dow JonesMar 14 18:50

Protalix BioTherapeutics FY Earnings Preview

Seeking AlphaMar 14 00:32

Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024

Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of...

PR NewswireMar 7 19:50

Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

PR NewswireFeb 23 19:50

ACON, PCSA and CORZ Among Pre-market Losers

Seeking AlphaJan 26 21:32

FDA's New Drug Approvals for 2023 Rise 51% From Last Year

Seeking AlphaDec 28, 2023 01:29

Protalix BioTherapeutics Issues 2024 Letter to Stockholders

Protalix BioTherapeutics, Inc. (NYSE American: PLX) today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders.

PR NewswireDec 26, 2023 19:50

Levicept Appoints Eliot Forster as CEO

Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a

GlobeNewswireNov 30, 2023 17:00

HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Protalix BioTherapeutics with a Buy and maintains $10 price target.

Analyst UpgradesNov 14, 2023 19:50

PLX: More Regulatory Approvals

Yahoo FinanceNov 7, 2023 17:25

American Well, Protalix BioTherapeutics Among Healthcare Movers

Seeking AlphaNov 6, 2023 23:01

Earnings Scheduled For November 6, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. • Gerdau (NYSE:GGB) is estimated to report qua

BenzingaNov 6, 2023 21:24

Protalix BioTherapeutics Q3 23 Earnings Conference Call At 8:30 AM ET

RTTNewsNov 6, 2023 20:30

Protalix BioTherapeutics Inc. Q3 Loss Drops in Line With Estimates

RTTNewsNov 6, 2023 19:56

Protalix BioTherapeutics GAAP EPS of -$0.04 Beats by $0.03, Revenue of $10.35M Beats by $2.71M

Seeking AlphaNov 6, 2023 19:53

Earnings Flash (PBDA) PROTALIX BIOTHERAPEUTICS Reports Q3 Revenue $10.3M

06:51 AM EST, 11/06/2023 (MT Newswires) -- Earnings Flash (PBDA) PROTALIX BIOTHERAPEUTICS Reports Q3 Revenue $10.3M

MT NewswiresNov 6, 2023 19:51